Tech Company M&A Transactions
Confluence Life Sciences Acquisition
Confluence Life Sciences, operating out of St. Louis, was purchased by Aclaris Therapeutics. Aclaris Therapeutics said the transaction price was $20 million.
Transaction Overview
Company Name
Acquired By
Announced On
8/9/2017
Transaction Type
M&A
Amount
$20,000,000
M&A Terms
At the closing, Aclaris paid approximately $10 million in cash and issued approximately 350,000 shares of its common stock, with a value of approximately $10 million on the closing date, to the former equityholders of Confluence.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4320 Forest Park Avenue
St. Louis, MO 63108
USA
St. Louis, MO 63108
USA
Phone
Email Address
Overview
Confluence Life Sciences is focused on rational drug designs to develop novel kinase inhibitors for use in human and animal healthcare.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Walter Smith
Chief Scientific Officer
Joseph Monahan
Controller
Jennifer Bohnert
Browse more venture capital transactions:
Prev: 8/9/2017: Super Heroic venture capital transaction
Next: 8/9/2017: Rothys venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs